Palvella Therapeutics (PVLA) director discloses fully vested stock option holding

Rhea-AI Filing Summary

PALVELLA THERAPEUTICS, INC. director John Doux filed an initial ownership report showing a stock option holding. The filing lists a fully vested stock option to acquire 10,364 shares of common stock at an exercise price of $7.14 per share, expiring on February 4, 2030.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Doux John

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,364 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Option underlying shares: 10,364 shares Exercise price: $7.14 per share Option expiration date: February 4, 2030 +1 more

4 metrics

Option underlying shares 10,364 shares Underlying common stock for reported stock option holding

Exercise price $7.14 per share Exercise price of the stock option

Option expiration date February 4, 2030 Expiration date of the stock option

Derivative position shares 10,364 shares Total shares underlying options held directly after reporting

Key Terms

Stock Option (Right to Buy), Common Stock, fully vested, exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

fully vested financial

"The stock option is fully vested."

exercise price financial

"exercisePrice: 7.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Doux John

(Last) (First) (Middle)

C/O PALVELLA THERAPEUTICS, INC.

353 W. LANCASTER AVENUE, SUITE 200

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/13/2026

3. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	02/04/2030	Common Stock	10,364	$7.14	D

Explanation of Responses:

1. The stock option is fully vested.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Kathleen A. McGowan, Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What insider position did John Doux report at PALVELLA THERAPEUTICS (PVLA)?

John Doux reported holding a stock option as a director of Palvella Therapeutics. The option covers 10,364 shares of common stock and is fully vested, meaning it is currently exercisable under the terms disclosed.

How many PALVELLA THERAPEUTICS (PVLA) shares are covered by John Doux’s option?

The reported stock option held by John Doux covers 10,364 shares of Palvella Therapeutics common stock. This figure reflects the underlying shares associated with the option position disclosed in the Form 3 filing.

What is the exercise price of John Doux’s PALVELLA THERAPEUTICS stock option?

The exercise price of John Doux’s stock option is $7.14 per share. This is the price at which he can buy Palvella Therapeutics common stock under the option, according to the Form 3 disclosure.

When does John Doux’s PALVELLA THERAPEUTICS stock option expire?

John Doux’s stock option expires on February 4, 2030. After that date, the option to acquire Palvella Therapeutics common stock at the stated exercise price of $7.14 per share will no longer be exercisable.

Is John Doux’s PALVELLA THERAPEUTICS stock option currently vested?

Yes, the filing states that the stock option held by John Doux is fully vested. Being fully vested means all 10,364 underlying shares are currently eligible to be acquired at the exercise price if he chooses to exercise.